AU2018348430B2 - Antibodies targeting PDL1 and methods of use thereof - Google Patents

Antibodies targeting PDL1 and methods of use thereof

Info

Publication number
AU2018348430B2
AU2018348430B2 AU2018348430A AU2018348430A AU2018348430B2 AU 2018348430 B2 AU2018348430 B2 AU 2018348430B2 AU 2018348430 A AU2018348430 A AU 2018348430A AU 2018348430 A AU2018348430 A AU 2018348430A AU 2018348430 B2 AU2018348430 B2 AU 2018348430B2
Authority
AU
Australia
Prior art keywords
seq
antibody
hsa
avelumab
pdl1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018348430A
Other languages
English (en)
Other versions
AU2018348430A1 (en
Inventor
Matthias Brock
Tea Gunde
Christian Hess
Alexandre Simonin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Numab Therapeutics AG
Original Assignee
Numab Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP17195781.4A external-priority patent/EP3470429A1/en
Application filed by Numab Therapeutics AG filed Critical Numab Therapeutics AG
Publication of AU2018348430A1 publication Critical patent/AU2018348430A1/en
Application granted granted Critical
Publication of AU2018348430B2 publication Critical patent/AU2018348430B2/en
Priority to AU2025271488A priority Critical patent/AU2025271488A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Liquid Crystal Substances (AREA)
AU2018348430A 2017-10-10 2018-10-09 Antibodies targeting PDL1 and methods of use thereof Active AU2018348430B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025271488A AU2025271488A1 (en) 2017-10-10 2025-11-28 Antibodies targeting PDL1 and methods of use thereof

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP17195781.4 2017-10-10
EP17195781.4A EP3470429A1 (en) 2017-10-10 2017-10-10 Antibodies targeting pdl1 and methods of use thereof
EP18167094 2018-04-12
EP18167094.4 2018-04-12
EP18180816.3 2018-06-29
EP18180816 2018-06-29
PCT/EP2018/077511 WO2019072869A1 (en) 2017-10-10 2018-10-09 PDL1 TARGETING ANTIBODIES AND METHODS OF USE THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025271488A Division AU2025271488A1 (en) 2017-10-10 2025-11-28 Antibodies targeting PDL1 and methods of use thereof

Publications (2)

Publication Number Publication Date
AU2018348430A1 AU2018348430A1 (en) 2020-03-12
AU2018348430B2 true AU2018348430B2 (en) 2025-09-04

Family

ID=63834022

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018348430A Active AU2018348430B2 (en) 2017-10-10 2018-10-09 Antibodies targeting PDL1 and methods of use thereof
AU2025271488A Pending AU2025271488A1 (en) 2017-10-10 2025-11-28 Antibodies targeting PDL1 and methods of use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025271488A Pending AU2025271488A1 (en) 2017-10-10 2025-11-28 Antibodies targeting PDL1 and methods of use thereof

Country Status (11)

Country Link
US (2) US12077588B2 (enExample)
EP (1) EP3694879A1 (enExample)
JP (3) JP7791650B2 (enExample)
KR (2) KR20250057935A (enExample)
CN (2) CN111225926B (enExample)
AU (2) AU2018348430B2 (enExample)
CA (1) CA3074802A1 (enExample)
IL (2) IL273578B1 (enExample)
MA (1) MA50353A (enExample)
SG (1) SG11202001654TA (enExample)
WO (1) WO2019072869A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018280679B2 (en) * 2017-06-05 2025-04-24 Numab Therapeutics AG Novel anti-HSA antibodies
PE20200849A1 (es) * 2017-10-10 2020-08-20 Numab Therapeutics AG Anticuerpo multiespecifico
US11208486B2 (en) * 2019-04-26 2021-12-28 I-Mab Biopharma Us Limited Human PD-L1 antibodies
EP3816185A1 (en) * 2019-11-04 2021-05-05 Numab Therapeutics AG Multispecific antibody directed against pd-l1 and a tumor-associated antigen
WO2024160721A1 (en) 2023-01-30 2024-08-08 Kymab Limited Antibodies
WO2024240690A2 (en) * 2023-05-19 2024-11-28 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
WO2025133389A1 (en) 2023-12-22 2025-06-26 Numab Therapeutics AG Antibody binding domains having specificity for lilrb2

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013079174A1 (en) * 2011-11-28 2013-06-06 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
WO2017118321A1 (en) * 2016-01-04 2017-07-13 Harbour Biomed Limited Anti-pd-l1 antibodies and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
DE3853515T3 (de) 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP0571613B1 (en) 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP2380906A2 (en) 1997-06-12 2011-10-26 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
BR0316880A (pt) * 2002-12-23 2005-10-25 Wyeth Corp Anticorpos contra pd-1 e usos dos mesmos
LT3279215T (lt) 2009-11-24 2020-04-10 Medimmune Limited Tiksliniai surišantys agentai prieš b7-h1
US10077312B2 (en) * 2013-05-10 2018-09-18 Numab Therapeutics AG CD3 and IL-23 receptor binding bispecific constructs and their use in the treatment of various diseases
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
IL293435A (en) 2015-06-15 2022-07-01 Numab Therapeutics AG Heterodimeric multispecific antibody format
CN108779176A (zh) 2016-01-11 2018-11-09 印希比股份有限公司 多价和多特异性41bb结合融合蛋白

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013079174A1 (en) * 2011-11-28 2013-06-06 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
WO2017118321A1 (en) * 2016-01-04 2017-07-13 Harbour Biomed Limited Anti-pd-l1 antibodies and uses thereof

Also Published As

Publication number Publication date
CA3074802A1 (en) 2019-04-18
US12077588B2 (en) 2024-09-03
CN111225926A (zh) 2020-06-02
JP2023166403A (ja) 2023-11-21
CN120248120A (zh) 2025-07-04
US20250066482A1 (en) 2025-02-27
AU2025271488A1 (en) 2026-01-08
KR20200063147A (ko) 2020-06-04
EP3694879A1 (en) 2020-08-19
IL273578A (en) 2020-05-31
WO2019072869A1 (en) 2019-04-18
KR20250057935A (ko) 2025-04-29
JP2025102791A (ja) 2025-07-08
IL273578B1 (en) 2025-11-01
JP2021501569A (ja) 2021-01-21
IL323510A (en) 2025-11-01
JP7791650B2 (ja) 2025-12-24
SG11202001654TA (en) 2020-03-30
JP7649825B2 (ja) 2025-03-21
CN111225926B (zh) 2025-03-14
MA50353A (fr) 2020-08-19
US20200283528A1 (en) 2020-09-10
AU2018348430A1 (en) 2020-03-12

Similar Documents

Publication Publication Date Title
US12202911B2 (en) Multispecific antibody comprising CD137 binding domain and PDL1 binding domain
AU2018348431B2 (en) Antibodies targeting CD137 and methods of use thereof
US20250066482A1 (en) Antibodies targeting pdl1 and methods of use thereof
EP3470429A1 (en) Antibodies targeting pdl1 and methods of use thereof
JP2025020172A (ja) Ｃｄ１３７を標的とする抗体およびその使用方法
EP3636320A1 (en) Antibodies targeting cd137 and methods of use thereof